India Glycols Targets ₹400 Crore EBITDA In 4-5 Years And 10X Long-Term Growth
India Glycols is positioning its core chemical business for high-margin scale-up, aiming for over ₹200 crore EBITDA in FY27E, ₹400 crore EBITDA in 4 to 5 years, and 10X top-line and bottom-line growth in 10 years on a renewable-carbon spine.
Market snapshot: India Glycols Limited has outlined ambitious financial growth targets, aiming to cross ₹200 crore in EBITDA for FY27E and reach ₹400 crore in EBITDA over the next 4 to 5 years. The company is also targeting a 10-fold expansion in revenue and EBITDA over a 10-year horizon following its structural demerger.
Data Snapshot
- FY27E EBITDA is targeted to exceed ₹200 crore, building on H1 FY27 continuing operations EBITDA of ₹113 crore.
- Medium-term plan sets a target of ₹400 crore EBITDA and ₹2,000 crore net revenue over 4 to 5 years.
- Long-term vision projects 10X growth in sales and EBITDA over 10 years through organic renewable-carbon chemical portfolio expansion.
What's Changed
- H1 FY27 continuing operations revenue reached ₹713 crore (up 26% YoY) with EBITDA rising 25% YoY to ₹113 crore.
- Structural demerger approved by NCLT separates non-chemical assets into distinct listed entities, leaving India Glycols focused on high-margin specialty chemicals.
Key Takeaways
- India Glycols is recalibrating into a pure-play bio-based specialty chemical powerhouse following corporate restructuring.
- EBITDA growth of 25% in H1 FY27 provides immediate operational momentum toward the ₹200 crore FY27E baseline.
- Long-term targets leverage global demand for green carbon alternatives and bio-based specialty materials without reliance on dilutive acquisitions.
SAHI Perspective
India Glycols' multi-phase EBITDA milestones reflect a deliberate strategy to capture market share in sustainable specialty chemicals. The separation of spirits and bio-pharma operations creates structural clarity, allowing the continuing chemical business to re-rate on pure-play chemical valuation metrics while driving compounding operational leverage.
Market Implications
The clear long-term roadmap enhances growth visibility for institutional investors tracking green chemicals. Operating leverage within bio-based specialty materials (where H1 FY27 revenue grew 43% YoY to ₹382 crore) supports margin expansion and long-term earnings resilience.
Trading Signals
Market Bias: Bullish
Positive earnings trajectory supported by 25% YoY EBITDA growth in H1 FY27 to ₹113 crore and strong forward target visibility of ₹400 crore EBITDA in 4 to 5 years.
Overweight: Specialty Chemicals, Bio-based Materials, Green Technology
Trigger Factors:
- Quarterly execution against the >₹200 crore FY27E EBITDA trajectory
- Capacity utilization shifts in Sustainable & Performance Chemicals segment
- Listing progress and price discovery of demerged entities
Time Horizon: Medium-term (3-12 months)
Industry Context
Global industrial demand is steadily shifting toward green-carbon chemical inputs and bio-glycols. As traditional petrochemical supply chains face ESG scrutiny, integrated bio-route manufacturers with scaled capabilities benefit from structural pricing premiums and multi-year supply contracts.
Key Risks to Watch
- Volatility in raw material feedstock costs including molasses and agro-intermediates
- Execution delays in scaling bio-based specialty capacity
- Macroeconomic slowdown impacting global chemical demand
Recent Developments
NCLT sanctioned the Scheme of Arrangement in July 2026, demerging the Spirits & Biofuel Undertaking into IGL Spirits Limited and the Biopharma Undertaking into Ennature Bio Pharma Limited. In November 2026, India Glycols reported Q2 FY27 continuing operations revenue of ₹358.18 crore with EBITDA growing 26% YoY to ₹52 crore.
Closing Insight
India Glycols' transition to a focused green specialty chemicals business backed by concrete 5-year and 10-year EBITDA milestones provides a clear operational framework for structural growth.
High Performance Trading with SAHI.
Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.
Open Free AccountRelated
Popular Vehicles Projects FY27 EBITDA Margin At 4.2% And FY28 Margin At 4.5%-4.6%
MCX Schedules One-on-One Investor Meeting With BlackRock On November 25
Jeena Sikho Lifecare Starts Operations at New Client Support Center in Noida
Dollar Industries Targets 11%-13% Revenue Growth And 11.5%-12.5% EBITDA Margin For FY27
Recent
Popular Vehicles Projects FY27 EBITDA Margin At 4.2% And FY28 Margin At 4.5%-4.6%
MCX Schedules One-on-One Investor Meeting With BlackRock On November 25
Jeena Sikho Lifecare Starts Operations at New Client Support Center in Noida
Dollar Industries Targets 11%-13% Revenue Growth And 11.5%-12.5% EBITDA Margin For FY27
Frequently Asked Questions (FAQs)
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.